The FDA has accepted Moderna's biologics license application for mRNA-1010, an mRNA-based influenza vaccine designed for adults aged 50 and older. The decision reverses the agency's previous refusal-to-file determination, with the FDA establishing an August 5 priority review completion date under the Prescription Drug User Fee Act (PDUFA). The acceptance signals the regulatory pathway forward for Moderna's messenger RNA approach to seasonal flu immunization.
Moderna's stock price increased 5.77% following the announcement, reflecting investor confidence in the vaccine candidate's regulatory progress. The development comes as the company reported fourth-quarter financial results that exceeded analyst expectations, posting a net loss narrower than projected alongside revenue of $678 million, surpassing consensus estimates. The stronger-than-anticipated financial performance and regulatory progress underscore the company's operational execution across its vaccine pipeline.
The mRNA-1010 candidate represents Moderna's expansion beyond its established COVID-19 vaccine franchise into seasonal infectious disease prevention. The priority review designation indicates the FDA's recognition of the vaccine's potential public health benefit, allowing for an expedited six-month review timeline rather than the standard ten-month period. The August 5 deadline provides a defined timeline for the agency's regulatory decision on the application.